Gevokizumab

Summary

Gevokizumab (CHEMBL1743026) is a phase-3 clinical-stage antibody; indicated across 10 conditions including behcet disease and pyoderma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 10 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743026
Name	Gevokizumab
Type	Antibody
Max phase	3

Also known as: Gevokizumab, VPM-087, VPM087, XOMA 052, XOMA-052, GEVOKIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Behcet disease	3	MONDO:0007191	EFO:0003780
pyoderma	3	MONDO:0002922	HP:0000999
uveitis	3	MONDO:0020283	EFO:1001231
acne	2	MONDO:0011438	EFO:0003894
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
osteoarthritis	2	MONDO:0005178	MONDO:0005178
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
scleritis	1	MONDO:0001718	MONDO:0001718

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE2	11
PHASE3	6
PHASE1/PHASE2	3
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01965145	PHASE3	TERMINATED	Efficacy of Gevokizumab in the Treatment of Patients With Behçet’s Disease Uveitis (EYEGUARD™-B)
NCT02258867	PHASE3	TERMINATED	Efficacy and Safety Study of Gevokizumab to Treat Behcet’s Disease Uveitis
NCT02315417	PHASE3	TERMINATED	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
NCT02318914	PHASE3	TERMINATED	A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
NCT02326740	PHASE3	TERMINATED	An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
NCT02375685	PHASE3	TERMINATED	Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
NCT00513214	PHASE1/PHASE2	COMPLETED	Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
NCT00777816	PHASE2	SUSPENDED	Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
NCT00998699	PHASE2	COMPLETED	Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
NCT01066715	PHASE2	COMPLETED	Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
NCT01144975	PHASE2	COMPLETED	Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
NCT01211977	PHASE1/PHASE2	WITHDRAWN	A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet’s Disease
NCT01498874	PHASE2	COMPLETED	Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
NCT01683396	PHASE2	COMPLETED	Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
NCT01788033	PHASE2	COMPLETED	Effects of XOMA 052 on Insulin Production in Type 1 Diabetes
NCT01835132	PHASE1/PHASE2	COMPLETED	Gevokizumab for Active Scleritis
NCT01882491	PHASE2	COMPLETED	Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
NCT01882504	PHASE2	COMPLETED	Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
NCT01950312	PHASE2	COMPLETED	The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
NCT05178576	PHASE2	WITHDRAWN	A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
NCT00541983	PHASE1	COMPLETED	Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus
NCT03798626	PHASE1	COMPLETED	Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
NCT02293564	Not specified	COMPLETED	Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).